ID CMB HC.PH.BIO.CMB
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | ALNY | United States of America | $41.76B | 1,735 |
| INSMED Inc | INSM | United States of America | $25.63B | 1,848 |
| BeOne Medicines Ltd. | ONC | Cayman Islands | $31.81B | 3,281 |
| BioNTech SE | BNTX | Germany | $23.13B | 656 |
| Roivant Sciences Ltd. | ROIV | Bermuda | $26.48B | 1,071 |
| Moderna, Inc. | MRNA | United States of America | $19.65B | 1,672 |
| INCYTE CORP | INCY | United States of America | $19.62B | 2,594 |
| Genmab | GMAB | Denmark | $17.77B | 2,961 |
| NEUROCRINE BIOSCIENCES INC | NBIX | United States of America | $13.12B | 2,183 |
| MADRIGAL PHARMACEUTICALS, INC. | MDGL | United States of America | $12.37B | 1,283 |
| EXELIXIS, INC. | EXEL | United States of America | $14.00B | 2,467 |
| Verona Pharma plc | VRNA | United Kingdom | $9.09B | 860 |
| Axsome Therapeutics, Inc. | AXSM | United States of America | $11.84B | 777 |
| ImmunityBio, Inc. | IBRX | United States of America | $9.17B | 559 |
| Grifols S.A. | GRF | Spain | $7.95B | 752 |
| HALOZYME THERAPEUTICS, INC. | HALO | United States of America | $8.48B | 1,509 |
| Krystal Biotech, Inc. | KRYS | United States of America | $10.08B | 568 |
| PharmaEssentia Corporation | 6446 | Taiwan | $16.18B | 2,396 |
| RHYTHM PHARMACEUTICALS, INC. | RYTM | United States of America | $5.93B | 906 |
| Mirum Pharmaceuticals, Inc. | MIRM | United States of America | $5.77B | 705 |
| Alkermes plc. | ALKS | United States of America | $8.66B | 2,014 |
| TG THERAPEUTICS, INC. | TGTX | United States of America | $5.35B | 1,129 |
| Apellis Pharmaceuticals, Inc. | APLS | United States of America | $5.25B | 1,283 |
| SK biopharmaceuticals Co., Ltd. | 326030 | South Korea | $4.93B | 504 |
| AMICUS THERAPEUTICS, INC. | FOLD | United States of America | $4.54B | 2,125 |
| CORCEPT THERAPEUTICS INC | CORT | United States of America | $9.10B | 1,943 |
| Hanmi Pharm. Co., Ltd. | 128940 | South Korea | $3.24B | 1,465 |
| Crinetics Pharmaceuticals, Inc. | CRNX | United States of America | $3.91B | 762 |
| ACADIA PHARMACEUTICALS INC | ACAD | United States of America | $4.49B | 1,449 |
| Kiniksa Pharmaceuticals International, plc | KNSA | United States of America | $4.55B | 827 |
| Legend Biotech Corp | LEGN | Cayman Islands | $6.66B | 426 |
| Liquidia Corp | LQDA | United States of America | $6.68B | 768 |
| Camurus | CAMX | Sweden | $3.53B | 477 |
| Telix Pharmaceuticals Ltd | TLX | United States of America | $3.42B | 1,144 |
| CATALYST PHARMACEUTICALS, INC. | CPRX | United States of America | $3.85B | 1,364 |
| MorphoSys AG Delisted | MOR | Germany | $2.95B | 2,029 |
| Arcutis Biotherapeutics, Inc. | ARQT | United States of America | $3.47B | 894 |
| Tarsus Pharmaceuticals, Inc. | TARS | United States of America | $2.65B | 709 |
| Travere Therapeutics, Inc. | TVTX | United States of America | $4.26B | 1,317 |
| SUPERNUS PHARMACEUTICALS, INC. | SUPN | United States of America | $2.65B | 1,204 |
| Bavarian Nordic | BAVA | Denmark | $2.16B | 2,492 |
| BIOCRYST PHARMACEUTICALS INC | BCRX | United States of America | $2.26B | 1,966 |
| Day One Biopharmaceuticals, Inc. | DAWN | United States of America | $2.22B | 504 |
| Syndax Pharmaceuticals Inc | SNDX | United States of America | $1.79B | 788 |
| Sarepta Therapeutics, Inc. | SRPT | United States of America | $2.15B | 1,537 |
| ADMA BIOLOGICS, INC. | ADMA | United States of America | $2.03B | 1,015 |
| AVADEL PHARMACEUTICALS PLC Delisted | AVDL | United States of America | $2.12B | 2,136 |
| Aurinia Pharmaceuticals Inc. | AUPH | Canada | $2.01B | 665 |
| SK Bioscience Co.,Ltd | 302440 | South Korea | $1.83B | 463 |
| Indivior Pharmaceuticals, Inc. | INDV | United Kingdom | $2.06B | 2,026 |
Other names for this activity, and where neighboring activities go instead.
No aliases listed.
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Also preclinical, drug developer
https://financialfilings.com/oics/CMB/
This page is keyed by the class ID CMB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.